It seems there may be some misunderstanding among us, but the company's communications have been clear regarding its strategies. I believe management has executed their plans effectively, although I understand why some retail investors may not fully grasp the situation.
RX5 consider the regulatory frameworks and the company's objectives, particularly in the context of Australia's history with over-the-counter (OTC) medications and the challenges of aligning a drug with regulatory requirements. Many drug developers have openly expressed skepticism about the feasibility of creating an OTC-compatible product with proven efficacy, especially at low doses.
It's important to recognize that the primary focus lies on RX7/9, which isn't subject to the same constraints as the Australian OTC regulations. These products promise superior effectiveness and dosage profiles compared to existing FDA-approved drugs, and the company is pursuing them in a capital-efficient manner, leveraging the National Health Index (NHI) without burdening shareholders with excessive dilution or cost of capital to do so (its currently free for us at the moment)
Australia's recent legislative changes have positioned it uniquely on the global stage, allowing for the prescription of psychedelics and associated clinical services, thereby generating real-world data (RWD). This presents a significant competitive advantage, unlike the cannabis industry, which faces intense global competition. - it was worth while for EMD to jump at this opportunity when it came up.
EMD remains committed to its shareholders' interests, opting not to dilute their ownership excessively. While the RX5 project remains an option for future consideration (it currently doesn't have the capital to continue), the current focus is on leveraging psychedelics for real-world data and clinical billings. The fact that the company has achieved revenue as a drug developer without an approved product is noteworthy and should instil confidence in investors.
EMD Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
